Secondary analysis of ALINA (257 patients, resected ALK-positive NSCLC): adjuvant alectinib vs platinum chemotherapy gave fewer serious treatment-related adverse events (2% vs 7%) and discontinuations (5% vs 13%); quality of life on alectinib improved (exploratory).
Secondary analysisn = 257
Dziadziuszko et al. Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial